You are here » Home » Companies » Company Overview » Suven Life Sciences Ltd

Suven Life Sciences Ltd.

BSE: 530239 Sector: Health care
NSE: SUVEN ISIN Code: INE495B01038
BSE LIVE 09:36 | 18 Dec 183.80 -0.75
(-0.41%)
OPEN

186.00

HIGH

186.00

LOW

180.00

NSE 09:21 | 18 Dec 181.10 -3.65
(-1.98%)
OPEN

185.00

HIGH

185.00

LOW

180.25

OPEN 186.00
PREVIOUS CLOSE 184.55
VOLUME 6732
52-Week high 230.00
52-Week low 155.00
P/E 18.62
Mkt Cap.(Rs cr) 2,340
Buy Price 183.45
Buy Qty 384.00
Sell Price 184.55
Sell Qty 143.00
OPEN 186.00
CLOSE 184.55
VOLUME 6732
52-Week high 230.00
52-Week low 155.00
P/E 18.62
Mkt Cap.(Rs cr) 2,340
Buy Price 183.45
Buy Qty 384.00
Sell Price 184.55
Sell Qty 143.00

Suven Life Sciences Ltd. (SUVEN) - Chairman Speech

Company chairman speech

Dear shareholders

IT HAS BEEN AN EXCITING TIME AT SUVEN FOR OUR PAINSTAKING EFFORTS OF MAKING REVENUEACCRETION PREDICTABLE AND PROFITABLE GROWTH SUSTAINABLE HAVE YIELDED HEARTENING RETURNS.

In fiscal 2016-17 two important things transpired. One we supplied commercialquantities for an approved NCE which was launched by our customer in the global markets.And two we continued to receive fees from a global pharmaceutical company for aformulated product. The coming together of these initiatives lends stability to ourbusiness and add important growth levers that promise to sustain profitable growth overthe coming years.

In fiscal 2017-18 we expect these flanking strategies to play a more meaningful rolein strengthening business profitability. This optimism stems from the interestingpossibilities. Our NCE vertical is at an inflection point. Four molecules are at variousstages in their development cycle – one is undergoing Phase II trial one is readyfor Phase II trial one has completed Phase I trial and one has entered Phase I trial.

And our success in delivering CRAMS projects to our global clients abily supports ourinvestments in NCE development.

Now there is an interesting development in the CRAMS business. Globally innovators arecherry-picking only those molecules for development which hold the potential of success.For us this means an increasing number of projects would move up the development valuechain (from Phase I to Phase II and to Phase III) making the base CRAMS business morerevenue accretive and profitable over medium to long term.

Message to shareholders

The current fiscal promises a lot of action in both verticals – CRAMS and NCEdevelopment. We remain hopeful that our planned initiatives would propel our CRAMSbusiness into the next orbit. We continue to remain steadfast on our resolve to unlockvalue from our steadily progressing NCE pipeline. We are confident that these strategieswill significantly increase wealth for our shareholders over the coming years.

Warm regards

Mr. Venkat Jasti

Chairman & CEO